Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors.
The BCL-2/BCL-XL inhibitor navitoclax has shown promise for the treatment of cancer but on-target toxicities have limited its utility. Recently, the generation of selective BCL-2 family inhibitors has enabled a careful dissection of BCL-2 biology, and early work indicates that these molecules have improved therapeutic profiles for the treatment of cancer.
Oncology Development , AbbVie, Chicago, IL, USA.
Joel D
JD
Leverson
A-1331852; apoptosis; chemical parsing; navitoclax; venetoclax